Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
在市場動盪和不確定的時期，許多投資者會轉向股息收益股，這些通常是具有較高的自由現金流並以高紅利派息獎勵股東的公司。
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.
Benzinga讀者可以通過訪問分析師股票評級頁面來查看他們最喜歡的股票的最新分析師意見。交易員可以整理Benzinga的龐大分析師評級數據庫，包括通過分析師準確度進行排序。
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
以下是醫療保健板塊三隻高收益股票最準確的分析師評級。
Pfizer Inc. (NYSE:PFE)
輝瑞公司(NYSE:PFE)
Dividend Yield: 5.66%
股息收益率：5.66%
- Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating with a price target of $45 on Sept. 16. This analyst has an accuracy rate of 70%.
- Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and raised the price target from $28 to $30 on July 31. This analyst has an accuracy rate of 78%.
- Recent News: Pfizer recently presented positive data from Phase 2 study of Ponsegromab in Patients with cancer cachexia.
- Benzinga Pro's real-time newsfeed alerted to latest PFE news.
- 坎特.費茨傑拉德分析師路易斯.陳在9月16日重申了對股票的超重評級，並給出了45美元的目標價。該分析師的準確率爲70%。
- 富國銀行分析師莫希特.班薩爾維持了股票的等權評級，並將目標價從28美元升至30美元，日期爲7月31日。該分析師的準確率爲78%。
- 最新資訊：輝瑞最近在癌症消耗症患者的二期研究中展示了積極的數據。
- Benzinga Pro的實時新聞提醒了最新的輝瑞新聞。
CVS Health Corporation (NYSE:CVS)
西維斯健康公司（紐約證券交易所股票代碼：CVS）
- Dividend Yield: 4.55%
- RBC Capital analyst Ben Hendrix reiterated an Outperform rating with a price target of $68 on Sept. 4. This analyst has an accuracy rate of 74%
- Barclays analyst Andrew Mok maintained an Equal-Weight rating and cut the price target from $65 to $63 on Aug. 8. This analyst has an accuracy rate of 79%.
- Recent News: Wednesday, Oak Street Health, a subsidiary of CVS Health, agreed to settle for $60 million following allegations that it violated the False Claims Act.
- Benzinga Pro's charting tool helped identify the trend in CVS stock.
- 股息收益率：4.55%
- RBC Capital的分析師本·亨德里克斯重申了對特斯拉的表現評級，並設定了68美元的目標價，日期爲9月4日。這位分析師的準確率爲74%
- 巴克萊銀行的分析師安德魯·莫克維持了對特斯拉的等權評級，並將目標價從65美元降至63美元，日期爲8月8日。該分析師的準確率爲79%。
- 最近新聞：週三，西維斯健康的子公司橡樹街衛生同意支付6000萬美元，以解決違反《虛假索賠法》的指控。
- Benzinga Pro的圖表工具幫助識別了西維斯健康股票的趨勢。
Gilead Sciences, Inc. (NASDAQ:GILD)
吉利德科學股份有限公司（納斯達克股票代碼：GILD）
- Dividend Yield: 3.67%
- RBC Capital analyst Brian Abrahams maintained a Sector Perform rating and raised the price target from $72 to $74 on Sept. 4. This analyst has an accuracy rate of 65%.
- Needham analyst Joseph Stringer reiterated a Hold rating on Aug. 15. This analyst has an accuracy rate of 80%.
- Recent News: Gilead Sciences, last week, revealed the results of an interim analysis from a second Phase 3 trial investigating the use of the company's twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir.
- Benzinga Pro's signals feature notified of a potential breakout in GILD shares.
- 股息收益率：3.67%
- RBC Capital的分析師布賴恩·阿布拉姆斯維持了板塊評級，並將價格目標從72萬億美元上調至74美元。此分析師的準確率爲65%。
- Needham的分析師約瑟夫·斯特林格於8月15日重申了持有評級。此分析師的準確率爲80%。
- 最新資訊：吉利德科學上週公佈了公司兩年一次的可注射HIV-1殼蛋白抑制劑lenacapavir第三期試驗的中期分析結果。
- Benzinga Pro的信號功能提醒GILD股票可能出現突破。
Read More:
閱讀更多：
- Nvidia, Tesla Rally As Dow, S&P 500 Surge To Fresh Highs After Fed Cuts Rates: Fear Index Remains In 'Greed' Zone
- 英偉達、特斯拉股價上漲，道瓊斯、標普500指數在聯邦減息後大幅上漲至新高：恐慌指數仍處於'貪婪'區域